Abstracts Archive - Page 652 of 2607 - ACR Meeting Abstracts

Abstract Number: 1511 • ACR Convergence 2022
Is There a Correlation Between Skin and Musculoskeletal Activity in Psoriatic Arthritis
Dafna Gladman¹, Ghaydaa Aldabie², Fangya Ma³, Mitchell Sutton⁴, Ker-Ai Lee³ and Richard Cook³, ¹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³University of Waterloo, Waterloo, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: The majority of patients with PsA present with skin manifestations first. Several studies have examined the relationship between activity/severity of skin and joint manifestations,…
Abstract Number: 1508 • ACR Convergence 2022
Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging
Siba Raychaudhuri¹, Yasser Abdelhafez², Dario Mazza³, Smriti Raychaudhuri⁴ and Abhijit Chaudhari³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, CA, ²University of California Davis, Sacramento, CA, ³UC Davis, School of Medicine, Sacramento, CA, ⁴VA Medical Center, Sacramento, CA
Background/Purpose: The enthesitis can be the earliest/primary inflammatory event in psoriatic arthritis (PsA). Clinically most of the entheses are not accessible and can't be assessed;…
Abstract Number: 1490 • ACR Convergence 2022
High Throughput Transcriptomic Analysis of Peripheral Mononuclear Cells Identifies Molecular Alterations Associated with the Active Clinical Phenotype of Axial Spondyloarthritis
Nuria Barbarroja¹, Laura Cuesta-Lopez¹, Carlos Pérez-Sánchez¹, Ariana Barberá-Betancourt², Ivan Arias-de la Rosa¹, Miriam Ruiz-Ponce¹, Clementina Lopez-Medina³, Ignacio Gómez-Garcia⁴, lourdes Ladehesa-Pineda⁵, Maria del Carmen Abalos-Aguilera⁶, Chary López-Pedrera⁷, Alejandro Escudero-Contreras¹ and Eduardo Collantes¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²University of Cambridge, Cambridge, United Kingdom, ³Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ⁴IMIBIC/University of Cordoba/Reina Sofia Hospital, Córdoba, Spain, ⁵Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ⁶Hospital Universitario Reina Sofia, Cordoba, Spain, ⁷Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain
Background/Purpose: A significant progress has recently been made in the identification of molecular profiles involved in the pathogenesis of chronic autoinflammatory diseases through the use…
Abstract Number: 1515 • ACR Convergence 2022
Assessing the Difference Between Radiographic Axial Spondylorthritis and Non-radiographic Axial Spondylorthritis in a Two-center Descriptive Study with Mexican Patients: The Influence of Clinical, Demographic, Laboratory and Clinimetric Features
John Londono¹, Gustavo Rodriguez-Salas², Igor Rueda-Cardenas³, Ana Maria Santos¹, Marta Mantilla¹, Juan Camilo Santacruz², Cesar Pachecho⁴, Gilberto Vargas-Alarcon⁵ and Ruben Burgos vargas⁶, ¹Spondyloarthropathies study group - Universidad de La Sabana - Hospital Militar Central, Bogotá, Colombia, ²Spondyloathropathies study group Universidad de La Sabana Hospital Militar Central, Bogotá, Colombia, ³Spondyloarthropathies study group - Universidad de LA Sabana - Hospital Militar Central, Colombia, Colombia, ⁴Universidad Autónoma de chihuahua, Chihuahua, Mexico, ⁵Insituto Nacional de Cardiología Ignacio Chavez, Ciudad de México, Mexico, ⁶hospital general de mexico, Ciudad de México, Mexico
Background/Purpose: Spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases that have some key features in common. According to ASAS, this condition is classified into…
Abstract Number: 1519 • ACR Convergence 2022
Using Galacetin-3 (Gal-3) and Cardiotrophin-1 (CT-1) for Early Detection of Primary Heart Involvement in Systemic Sclerosis as Seen on Cardiac MRI
Erin Chew¹, Sarah Wood¹, Bibin Varghese¹, Christopher Chew², erin wilfong¹ and Tracy Frech¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Primary heart involvement in systemic sclerosis (SSc-pHI) is characterized by myocardial inflammation with resultant fibrosis that is not secondary to ischemic heart disease or…
Abstract Number: 1517 • ACR Convergence 2022
Value of the Anti-CD74 Antibodies for the Diagnosis of Axial Spondyloarthritis: Results of a Prospective Study in Patients with Suspicious Low Back Pain
Nelly Ziade¹, Avin Maroof², Antonella Abi Najm¹, Torsten Witte³ and Xenofon Baraliakos⁴, ¹Saint-Joseph University, Beirut, Lebanon, ²Rizgary Teaching Hospital - Erbil, Erbil, Iraq, ³MH-Hannover, Hannover, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Patients with axial spondyloarthritis (axSpA) are diagnosed late, partially due to the absence of a reliable biomarker. The diagnostic value of the anti-CD74 antibodies…
Abstract Number: 1522 • ACR Convergence 2022
The Collaborative National Quality and Efficacy Registry for Scleroderma: Association of Medication Use on Gastrointestinal Tract Symptoms in Early Disease
Sarah Luebker¹, Tracy Frech¹, Shervin Assassi², Jessica Gordon³, Elana Bernstein⁴, Virginia Steen⁵, Ami Shah⁶, Laura Hummers⁷, Carrie Richardson⁸, Dinesh Khanna⁹, Flavia Castelino¹⁰, Lorinda Chung¹¹, Faye Hant¹², Vicki Shanmugam¹³, John VanBuren¹⁴, Jessica Alvey¹⁴, Monica Harding¹⁴, Luke Evnin¹⁵ and Nora Sandorfi¹⁶, ¹Vanderbilt University Medical Center, Nashville, TN, ²McGovern Medical School, University of Texas, Houston, TX, ³Hospital for Special Surgery, New York, NY, ⁴Columbia University, New York, NY, ⁵Georgetown University School of Medicine, Washington, DC, ⁶Johns Hopkins Rheumatology, Baltimore, MD, ⁷Johns Hopkins Univerisity, Baltimore, MD, ⁸Northwestern University, Chicago, IL, ⁹Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹Stanford University, Stanford, CA, ¹²Medical University of South Carolina, Charleston, SC, ¹³George Washington University, Washington, DC, ¹⁴University of Utah, Salt Lake City, UT, ¹⁵Scleroderma Research Foundation, Brisbane, CA, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Gastrointestinal tract (GIT) symptoms are common amongst systemic sclerosis (SSc) patients.1 The Scleroderma Clinical Trials Consortium University of California Los Angeles Gastrointestinal Tract Questionnaire…
Abstract Number: 1521 • ACR Convergence 2022
Long-term Follow-Up of Participants of the Phase II Study That Evaluated Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis (ASSET Trial)
Nadine Sarsam¹, Sindhu R. Johnson², Lorinda Chung³, Suzanne Kafaja⁴, Janet Pope⁵, Robyn Domsic⁶, Maureen Mayes⁷, Nora Sandorfi⁸, Virginia Steen⁹, Flavia Castelino¹⁰, Faye Hant¹¹, Suiyuan Huang¹ and Dinesh Khanna¹², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, Department of Medicine, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western and Mount Sinai Hospitals; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ³Stanford University, Stanford, CA, ⁴UCLA Department of Medicine, Division of Rheumatology, Los Angeles, CA, ⁵University of Western Ontario, London, ON, Canada, ⁶University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Georgetown University School of Medicine, Washington, DC, ¹⁰Massachusetts General Hospital, Boston, MA, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Abatacept (ABA) is a cytotoxic T-lymphocyte-associated molecule-4 immunoglobulin fusion protein which has been shown to induce regression of dermal fibrosis in patients with systemic…
Abstract Number: 1520 • ACR Convergence 2022
Rituximab and Tocilizumab and Their Effect on Lung Disease Progression in Scleroderma. a Retrospective Cohort Study at a Single Centre
Nina Goldman¹, Aoife Tynan², Shivani Shah², Claire Beesley¹, Rizgar Mageed³, Chris Denton¹ and Voon Ong⁴, ¹University College London, London, United Kingdom, ²Division of Medicine, Department of Rheumatology, University College London, London, United Kingdom, ³Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, ⁴UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in systemic sclerosis (SSc). Emerging evidence suggests a beneficial effect of tocilizumab…
Abstract Number: 1514 • ACR Convergence 2022
Self-referral Strategy for Early Diagnosis of Axial Spondyloarthritis- Preliminary Analysis from Finding Axial Spondyloarthritis Study
Abhijeet Danve, Yale University, New Haven, CT
Background/Purpose: Lack of timely rheumatology referral for suspected axial spondyloarthritis (axSpA) is a major contributor to delayed diagnosis in patients with chronic back pain (CBP).…
Abstract Number: 1524 • ACR Convergence 2022
Risk Factors for Lung Function Decline in Systemic Sclerosis Interstitial Lung Disease in a Large Single-Center Cohort
Ahmad Ramahi¹, Alain Lescoat², David Roofeh¹, Vivek Nagaraja¹, Rajaie Namas³, Suiyuan Huang¹, John Varga¹, David O’Dwyer¹, Bonnie Wang¹, Kevin Flaherty¹, Ella Kazerooni¹ and Dinesh Khanna⁴, ¹University of Michigan, Ann Arbor, MI, ²CHU Rennes - University Rennes 1, Rennes, France, ³Medical Subspecialties Institute, Division of Rheumatology at Cleveland Clinic, Abu Dhabi, United Arab Emirates, ⁴Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is the leading cause of scleroderma-related mortality. This work identifies factors associated with SSc-ILD decline on pulmonary function…
Abstract Number: 1513 • ACR Convergence 2022
Identification of MRI Lesions Indicative of Spondyloarthritis Diagnosis from the Axial Spondyloarthritis International Society (ASAS) MRImagine Multi-Reader Scoring Dataset Using the Chi-Squared Automatic Interaction Detection Algorithm (CHAID)
Stephanie Wichuk¹, Walter P Maksymowych², Robert G Lambert¹, Abhilash Hareendranathan³ and Jacob Jaremko¹, ¹University of Alberta, Edmonton, AB, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Several types of active and structural lesions have been identified on sacroiliac joint MRI of spondyloarthritis (SpA) patients. Various combinations of these lesions may…
Abstract Number: 1445 • ACR Convergence 2022
Gastrointestinal Manifestations in Systemic Lupus Erythematosus Are Associated with High Disease Activity and Mortality: A Nationwide Cohort Study from India
Pankti Mehta¹, Akansha Srivastava², Amita Aggarwal², Liza Rajasekhar³, Vineetha Shobha⁴, Chengappa Kavadichanda⁵, ASHISH JACOB MATHEW⁶, Parasar Ghosh⁷, Bidyut Das⁸, Avinash Jain⁹, Ranjan Gupta¹⁰ and Manish Rathi¹¹, ¹King George's Medical University, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Nizam's Institute of Medical Sciences, Madhapur, India, ⁴St. John’s Medical College Hospital, Bangalore, India, ⁵JIPMER, Pondicherry, Puducherry, India, ⁶Christian Medical College, Vellore, Vellore, India, ⁷Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁸SCB medical college, Cuttack, India, ⁹SMS Medical College, Lucknow, India, ¹⁰All India Institute of Medical Sciences, New Delhi, India, ¹¹PGIMER Chandigarh, Chandigarh, India
Background/Purpose: Gastrointestinal (GI) manifestations of Systemic Lupus Erythematosus (SLE) although rare are often severe. These are difficult to directly attribute to SLE as they can…
Abstract Number: 1531 • ACR Convergence 2022
Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Three-Year Data from SENSCIS-ON
Yannick Allanore¹, Madelon Vonk², Oliver Distler³, Arata Azuma⁴, Maureen Mayes⁵, Alexandra James⁶, Veronika Kohlbrenner⁷, Margarida Alves⁸, Dinesh Khanna⁹ and Kristin Highland¹⁰, ¹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁴Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, ⁵Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, ⁶Elderbrook solutions GmbH, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁷Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA, Ridgefield, CT, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁹Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁰Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH
Background/Purpose: In the randomized placebo-controlled SENSCIS trial in patients with SSc-ILD, nintedanib reduced the rate of decline in forced vital capacity (FVC) (mL/year) over 52…
Abstract Number: 1527 • ACR Convergence 2022
Maintained Complete B Cell Depletion Is Associated with Rituximab Efficacy in Connective Tissue Disorder Interstitial Lung Disease
Jérôme Avouac¹, Roba Ghossan², Omar Al Tabaa³, Alice Combier², Alexia Steelandt², Marion Thomas⁴ and Yannick Allanore⁵, ¹University of Paris, Paris, France, ²Hôpital Cochin, AP-HP.Centre - Université Paris Cité, Paris, France, ³Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁵Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: The benefit of RTX has been suggested for interstitial lung disease (ILD) associated with connective tissue disorders (CTD). Preliminary data have suggested that B…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].